Cite
HARVARD Citation
Dawson, K. et al. (n.d.). Preliminary biomarker and pharmacokinetic analysis from the completed dose escalation part of the first-in-human Phase I study evaluating MP0250, a multi-DARPin® blocking HGF and VEGF-A, in patients with advanced solid tumors. European journal of cancer. pp. S133-. [Online].